Albany Molecular Research, Inc. (AMRI) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 11 PAGES: 44

More Info
									        Albany Molecular Research, Inc. (AMRI) - Financial and Strategic SWOT
                                 Analysis Review
        Reference Code: GDPH7874FSA                                                                                           Publication Date: APR 2013

          26 Corporate Circle                                Phone              +1 518 5122000                  Revenue         207.7 (million USD)
          Albany, NY                                         Fax                +1 518 5122020                  Net Profit      -32.30 (million USD)
          12203                                              Website            www.amriglobal.com              Employees       1,329
                                                                                                                                Pharmaceuticals            &
          United States                                      Exchange           AMRI [NASDAQ]                   Industry
                                                                                                                                Healthcare

       Company Overview
       Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization that offers integrated drug
       discovery, development and manufacturing services. AMRI’s core business consists of a fee-for-service contract services. Some
       of the key services the company offers include drug discovery and development, cGMP manufacturing at its various locations
       across the US and Asia, process scale-up development and aseptic filling services for projects in various stages of development
       and Analytical Services.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Albany Molecular Research, Inc., SWOT Analysis
         Thomas E. D'Ambra, Ph.D.            Chairman                                 Strengths                              Weaknesses
         Kevin O'Connor                      Director
                                                                                      Integrated Project Solution            Huge Debt
         Arthur J. Roth                      Director
                                                                                      In house R&D Initiatives
         Veronica G.H. Jordan                Director
         Una S. Ryan                         Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Collaborations and Agreements Lengthy Drug Approval Process
       Share Data
                                                                                      Rising Healthcare Expenditure Intense Competition
         Albany Molecular Research, Inc.
                                                                                      in the US
        Share Price (USD) as on 28-Mar-                                10.51
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -1.08        GlobalData
        Market Cap (million USD)                                         325
        Enterprise Value (million USD)                                   317
        Shares Outstanding (million)                                       31
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 13, 2013         AMRI And Codexis Announce Technology
                                                                                                           Collaboration
                                                                                      Feb 12, 2013         AMRI Reports Revenue Of $67.2m In Q4 2012
                                                                                      Jan 07, 2013         AMRI Relocates Jobs From Washington Lab
                                                                                                           To Albany, Buffalo
                                                                                      Nov 30, 2012         AMRI Realigns Discovery Services To Support
                                                                                                           Customer Demand
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData

       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Albany Molecular Research, Inc. (AMRI) - Financial and Strategic                                                                Reference Code: GDPH7874FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Albany Molecular Research, Inc. - Key Facts ..................................................................................................................................... 5
       Albany Molecular Research, Inc. - Key Employees ............................................................................................................................ 6
       Albany Molecular Research, Inc. - Key Employee Biographies .......................................................................................................... 7
       Albany Molecular Research, Inc. - Major Products and Services ....................................................................................................... 8
       Albany Molecular Research, Inc. - Pharmaceutical Pipeline Products Data ..................................................................................... 10
          Albany Molecular Research, Inc., Pipeline Products by Therapy Area ......................................................................................... 10
          Albany Molecular Research, Inc., Pipeline Products by Development Phase............................................................................... 11
       Albany Molecular Research, Inc. - History........................................................................................................................................ 13
       Albany Molecular Research, Inc. - Company Statement .................................................................................................................. 16
       Albany Molecular Research, Inc. - Locations And Subsidiaries........................................................................................................ 18
          Head Office ................................................................................................................................................................................... 18
          Other Locations & Subsidiaries ..................................................................................................................................................... 18
       Albany Molecular Research, Inc. - Key Manufacturing Facilities ...................................................................................................... 19
       Section 2 – Company Analysis ......................................................................................................................................................... 20
       Albany Molecular Research, Inc. - Business Description ................................................................................................................. 20
       Albany Molecular Research, Inc. - SWOT Analysis .......................................................................................................................... 21
          SWOT Analysis - Overview........................................................................................................................................................... 21
          Albany Molecular Research, Inc. - Strengths ................................................................................................................................ 21
             Strength - Integrated Project Solution ....................................................................................................................................... 21
             Strength - In house R&D Initiatives ........................................................................................................................................... 21
             Strength - Broad Pharmaceutical Service Offerings .................................................................................................................. 21
          Albany Molecular Research, Inc. - Weaknesses ........................................................................................................................... 21
             Weakness - Huge Debt ............................................................................................................................................................. 21
          Albany Molecular Research, Inc. - Opportunities .......................................................................................................................... 22
             Opportunity - Collaborations and Agreements .......................................................................................................................... 22
             Opportunity - Rising Healthcare Expenditure in the US............................................................................................................. 22
             Opportunity - Changing Demographics ..................................................................................................................................... 22
          Albany Molecular Research, Inc. - Threats ................................................................................................................................... 22
             Threat - Lengthy Drug Approval Process .................................................................................................................................. 22
             Threat - Intense Competition ..................................................................................................................................................... 23
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 23
       Albany Molecular Research, Inc. - Key Competitors ........................................................................................................................ 24
       Section 3 – Company Financial Ratios ............................................................................................................................................. 25
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 25
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 25
       Performance Chart ........................................................................................................................................................................... 27
       Financial Performance...................................................................................................................................................................... 27
       Financial Ratios - Interim Ratios....................................................................................................................................................... 28
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 29
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 30
          Albany Molecular Research, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ........................................ 30


Albany Molecular Research, Inc. (AMRI) - Financial and Strategic                                                                                                 Reference Code: GDPH7874FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Albany Molecular Research, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ........................................ 31
       Albany Molecular Research, Inc., Recent Deals Summary .............................................................................................................. 32
       Section 5 – Company’s Recent Developments ................................................................................................................................ 33
          Albany Molecular Research, Inc., Recent Developments ............................................................................................................. 33
             Feb 13, 2013: AMRI And Codexis Announce Technology Collaboration .................................................................................. 33
             Feb 12, 2013: AMRI Reports Revenue Of $67.2m In Q4 2012 ................................................................................................. 33
             Jan 07, 2013: AMRI Relocates Jo
								
To top